Global Personalized Medicine Market Size study & Forecast, by Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness) and Regional Analysis, 2022-2029

Global Personalized Medicine Market Size study & Forecast, by Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness) and Regional Analysis, 2022-2029

Global Personalized Medicine Market is valued approximately USD 514.33 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.95% over the forecast period 2022-2029. Personalised medicine, is also known as precision medicine, it divides people into distinct groups and then tailors medical decisions, therapies, practises, and/or products to each patient depending on that patient's expected response or illness risk. The market is majorly driven by rising demand for novel drug discovery, rising number of cancer cases and other diseases. Along with this, growing number of clinical trials is driving the growth for the market over the forecast period 2022-2029. Moreover, rising initiatives by key market players is creating lucrative growth opportunity for the market over the period.

It is also projected that the rising prevalence of rare diseases will accelerate market expansion. The development of numerous individualized medical treatments and therapeutic activities has been made possible by advances in our understanding and correlation of the properties of the human genome. For instance, a research study conducted at the University of California, Irvine in September 2022 offered a unique method for treating inherited retinal diseases (IRDs) by applying precise genome editing that is highly tailored to the needs of an individual. Along with this, there are an increasing number of companion diagnostics that have received FDA approval. For example, Roche received U.S. FDA clearance in October 2020 to expand the use of the Cobas EGFR Mutation Test for the treatment of non-small cell lung cancer. However, the high cost of Personalized Medicine stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Personalized Medicine Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2021, North America had the largest share. This is linked to funding from large pharmaceutical companies and research organisations. All types of ailments are now best treated with personalised medicine, which is why drug discovery and research into any condition now include it. In the region, personalised medicine is advancing for diagnostic purposes. Due to rising demand for personalised diagnostics and novel treatment medications to combat the region's rising disease prevalence, Asia Pacific is anticipated to have the fastest expanding segment over the course of the projection year.

Major market player included in this report are:
GE Healthcare
Illumina, Inc.
ASURAGEN, INC.
Abbott
Dako A/S
Exact Sciences Corporation
Danaher Corporation (Cepheid, Inc.)
Decode Genetics, Inc.
QIAGEN
Exagen Inc.

Recent Developments in the Market:
 In order to create personalised nutrition for healthcare providers and their subjects using a high-end technology interface, Panaceutics Nutrition and Viocare announced a collaborative agreement in January 2022. This agreement will combine Viocare's nutrition assessment software with personalised nutrition supplementation to create an end-to-end service platform.
 Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) in Germany joined up in February 2022 to apply precision medicine in healthcare in strategic, structural, and content-specific ways.
Global Personalized Medicine Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Personalized Medicine Diagnostics
Personalized Medicine Therapeutics
Personalized Medical Care
Personalized Nutrition & Wellness

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World


Companies Mentioned
GE Healthcare
Illumina, Inc.
ASURAGEN, INC.
Abbott
Dako A/S
Exact Sciences Corporation
Danaher Corporation (Cepheid, Inc.)
Decode Genetics, Inc.
QIAGEN
Exagen Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.